Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

108 results about "Antiprotozoal" patented technology

Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection. Protozoans have little in common with each other (for example, Entamoeba histolytica, a unikont eukaryotic organism, is less closely related to Naegleria fowleri, a bikont eukaryotic organism, than it is to Homo sapiens, which belongs to the unikont phylogenetic group) and so agents effective against one pathogen may not be effective against another.

Methods of promoting immunopotentiation and preparing antibodies with anti-CD3 antibodies

Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and / or otherwise modify immune responses, and method for their preparation and use in vivo. Immunopotentiating agents can be single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates wherein the immunopotentiating agent is chemically coupled to the compound against which an immune response is desired. Examples of immunopotentiating agents include monoclonal antibodies, such as anti-CD3, anti-CD2) and anti-CD5 antibodies, and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. The compounds against which an immune response can be generated, which may be the second component in a heteroconjugate, include compound from abnormal or diseased tissues such as tumors, or infectious agents, such as viruses, bacteria, fungi, protozoal or metozoal parasites, and can be obtained by natural or recombinant means. Methods of using the invention to prepare monoclonal antibodies are particularly disclosed.
Owner:MACROGENICS INC

Monoclonal antibodies to Sarcocystis neurona and uses therefor

The present invention is directed to particular monoclonal antibodies that find use in the identification and purification of Sarcocystis neurona and related antigens. In particular, these antibodies permit the diagnosis of Sarcocystis related diseases such as equine protozoal myeloencephalitis (EPM).
Owner:UNIVERSITY OF MISSOURI

Vaccines against cancer and infectious diseases

A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.
Owner:IMMUNOMEDICS INC

Controlling zoonotic disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi

The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and / or pathogens and can be employed to limit the zoonotic diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, and genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals, and plants.
Owner:TURTLE BEAR HLDG LLC

Personalized site-specific immunomodulation

The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
Owner:QU BIOLOGICS INC

Malaria plasmodium antigen polypeptide se36, method of purifyng the same and vaccine and diagnostic with the use of the thus obtained antigen

The present invention provides a polypeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifying said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies specifically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.
Owner:THE RES FOUND FOR MICROBIAL DISEASES OFOSAKA UNIV +1

Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi

The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and / or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants.
Owner:TURTLE BEAR HLDG LLC

Modified sophorolipids combinations as antimicrobial agents

InactiveUS20130142855A1Higher antimicrobial activity towardsEnhanced anti-microbial activityBiocideLavatory sanitoryProtozoaMicroorganism
A method to control, inhibit, and kill pathogens and normal microbial strains that includes, but not limited to plant, animal and human pathogens, biofilm forming microbes, biofouling microbes, algae, fungi, bacteria, virus and protozoa using natural SL, MSL derivative and combinations thereof encompassed by the combination invention.
Owner:SYNTHEZYME

Method for Treating Systemic Bacterial, Fungal and Protozoan Infection

A treatment for the diseases that are accompanied by quantitative and qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNASE enzyme may be further applied in a dose and regime that provide a DNA hydrolytic activity measured in blood plasma exceeding 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.
Owner:CLS THERAPEUTICS

Recombinant expression of heterologous nucleic acids in protozoa

The ciliated protozoan Tetrahymena exemplifies a recombinant system for the expression of heterologous nucleic acids, preferably on the plasma membrane surface. Integration of a heterlogous nucleic acid into the β-tubulin gene, BTU1, of a paclitaxel-sensitive T. thermophila mutant that possesses btu1-1K350M β-tubulin allele allows screening for transformants using negative selection, as transformants have restored paclitaxel resistance. Transgenic ciliated protozoa of the invention can serve as live vaccines. For example, transgenic Tetrahymena expressing Ichthyophthirius multifiliis i-antigen protein on their surface are effective vehicles for vaccination of freshwater fish against infection by I. multifiliis.
Owner:GEORGIA UNVERSITY OF RES FOUND INC THE

Endoparasite control agent

An object of the present invention is to provide a novel endoparasite control agent as a parasiticide, an antiprotozoal or the like. Provided is an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I):(wherein Het represents a 5- or 6-membered heterocyclic group), ora salt thereof as an active ingredient.
Owner:THE UNIV OF TOKYO +1

Methods of Treating An Infection with Nitric Oxide

The present invention provides methods of treating bacterial, viral, protozoan, parasitic, arthropod and fungal infections by applying gaseous nitric oxide to a patient having an infection. The present invention further provides improved methods of treating bacterial, viral, protozoan, parasitic and fungal infections by applying gaseous nitric oxide, in combination with oxygen, to a patient having an infection.
Owner:CARDINAL HEALTH INC +1

Method for controlling protozoa that harbor bacteria

A method for controlling protozoa trophozites and cysts wherein biocides or control agents are encapsulated within microcapsules or manufactured into the core of liposomes, thereafter the biocide containing microcapsules or liposomes are then introduced into an aqueous system.
Owner:BL TECH INC

Method For Measuring Protozoan Oocyst and Detecting Reagent

ActiveUS20080199884A1Improve accuracyRapidly and conveniently detectingBiological testingProtozoaAnalyte
The present invention provides a method for measuring oocyst of protozoa, such as Cryptosporidium, in an environment sample with high sensitivity at low cost within a short period of time; and a detecting reagent for use therein.Magnetic fine particles of 5 to 500 nm particle diameter having, immobilized thereto, binding factors for specific recognition of oocyst are added to an analyte containing a protozoan oocyst to form oocyst / binding factor / magnetic fine particle complexes by using a binding reaction to the oocyst, the formed complexes are recovered by a magnetic separation, and the protozoan oocysts contained in the complexes are assayed. Further, there is provided, for conducting the above method, a reagent for detecting protozoan oocysts comprising magnetic fine particles of 5 to 500 nm particle diameter having, immobilized thereto, antibodies against oocysts or binding factors for recognizing the antibodies.
Owner:KOBE UNIV +1

Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties

The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.
Owner:UNIV OF CONNECTICUT

Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors

The present invention relates to means and method for isolating naturally-occurring microorganisms (non-pathogenic bacteria, yeasts or fungi) capable of binding toxins from microorganisms such as bacteria, viruses, fungi, yeasts, or protozoans and / or receptors for these toxins on the surface of mammalian cells, thereby making these receptors inaccessible for said toxins. The naturally-occurring microorganisms that are obtainable by the means and methods of the present invention can be used for adsorbing toxins from pathogenic microorganisms and / or blocking receptors for such toxins on the surface of mammalian cells. These toxin-receptor interactions are known to be critical for disease pathogenesis, making both the toxins and receptors a target for the naturally-occurring microorganisms of the present invention.
Owner:ULSEMER PHILIPPE +2

Engineered opsonin for pathogen detection and treatment

The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Polymer composition containing natural bioactive principles for use in pharmaceutical and cosmetic formulations

The present invention relates to a polymer composition containing natural bioactive principles, in particular propolis extract. The present composition is of value because it exhibits antimicrobial (antibacterial, antifungal, antiviral and antiprotozoal), wound healing, anti-inflammatory, antioxidising and moisturising properties. The composition according to the present invention can be used in pharmaceutical and cosmetic formulations, thus being useful for odontological treatments (of caries, gingivitis, periodontitis, bad breath, aphthae, oral stomatitis) and for the treatment of affections of the skin and mucous membranes. The present composition also contains biocompatible and biodegradable polymers that allow controlled release of the active principles. For this purpose, the product can be provided in the form of different formulations: spray, mouthwash, toothpaste, oral-base cream, lotions, creams, gels, inter alia.
Owner:BIOACTIVE BIOMATERIAIS LTDA

Leishmania as carriers for the delivery of proteins and peptides

InactiveUS7261887B2BiocideProtozoaProtozoaHaem biosynthesis
Methods for delivering potentially therapeutic or prophylactic protein and peptide agents to mammalian cells are provided. The agents are delivered by mutant trypanosomatid protozoa that have been genetically manipulated to code for such protein or peptide agents. The mutant protozoa additionally lack certain enzymes within the heme biosynthetic pathway, making the mutants susceptible to porphyria and eventual lysis.
Owner:ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products